JP Morgan Healthcare Conference Giovanni Caforio Chief Executive - - PowerPoint PPT Presentation

jp morgan healthcare conference
SMART_READER_LITE
LIVE PREVIEW

JP Morgan Healthcare Conference Giovanni Caforio Chief Executive - - PowerPoint PPT Presentation

JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 NOT FOR PRODUCT PROMOTIONAL USE 1 Forward-Looking Information This presentation contains statements about the Companys future plans and prospects


slide-1
SLIDE 1

NOT FOR PRODUCT PROMOTIONAL USE

JP Morgan Healthcare Conference

January 12, 2016

Giovanni Caforio

Chief Executive Officer

1

slide-2
SLIDE 2

NOT FOR PRODUCT PROMOTIONAL USE

Forward-Looking Information

This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as

  • f any subsequent date. While we may elect to update forward-looking

statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.

2 2

slide-3
SLIDE 3

NOT FOR PRODUCT PROMOTIONAL USE

Our Strategic Foundation

People helping patients in their fight against serious disease

IN N OVATE IMPR O VE IN TEGR ATE

Diversified Specialty BioPharma

Best of BIOTECH Best of PHARMA

3

slide-4
SLIDE 4

NOT FOR PRODUCT PROMOTIONAL USE

2015: Beginning A New Chapter

Leading in Immuno-Oncology Diversified in-line portfolio A Strong Foundation for Future Growth

Early Trial Stops

3

FDA Approvals

7 43 Global launches

4

slide-5
SLIDE 5

NOT FOR PRODUCT PROMOTIONAL USE

Drive business performance Leadership in Immuno-Oncology Diversify for long-term growth Business Development and Capital Allocation

Strategic Priorities

5

slide-6
SLIDE 6

NOT FOR PRODUCT PROMOTIONAL USE

2015: Leading in Immuno-Oncology

MELANOMA LUNG RENAL

  • Only PD-1 indicated for all 2nd line

NSCLC patients

  • No testing requirement
  • Strong access and reimbursement
  • Broad range of treatment options (Mono and

combination therapy, 1st and 2nd line, adjuvant)

  • First I-O combination regimen approved
  • First I-O agent in 2nd line
  • Meaningful improvement over a standard of care

6

slide-7
SLIDE 7

NOT FOR PRODUCT PROMOTIONAL USE

2015: Leading in Immuno-Oncology

Strong US commercial execution

1/2 1/9 1/16 1/23 1/30 2/6 2/13 2/20 2/27 3/6 3/13 3/20 3/27 4/3 4/10 4/17 4/24 5/1 5/8 5/15 5/22 5/29 6/5 6/12 6/19 6/26 7/3 7/10 7/17 7/24 7/31 8/7 8/14 8/21 8/28 9/4 9/11 9/18 9/25 10/2 10/9 10/16 10/23 10/30 11/6 11/13 11/20 11/27 12/4 12/11

I-O Weekly Sales Trends

Total IO Market – Weekly IMS DDD + Xponent

Yervoy Opdivo BMS I-O Portfolio Keytruda

Note: This information is an estimate derived from the use of information under license from the following IMS Health information services: Xponent & DDD weekly dollars, for the period of 1/2/2015 through 12/31/2015. IMS expressly reserves all rights, including rights of copying, distribution and republication.

7

slide-8
SLIDE 8

NOT FOR PRODUCT PROMOTIONAL USE

2016: Leading in Immuno-Oncology

Tumor Study Design Hodgkin Lymphoma

CheckMate -205

Monotherapy single arm study in second line Head and Neck

CheckMate -141

Monotherapy vs. standard of care in second line Non-Hodgkin Lymphoma

CheckMate -139

Monotherapy single-arm study in relapsed/refractory diffuse large B-cell lymphoma Bladder

CheckMate -275

Monotherapy single arm study in second line bladder Glioblastoma

CheckMate -143

Monotherapy vs. standard of care in recurrent glioblastoma 1L NSCLC

CheckMate -026

Monotherapy vs. chemo in first-line PD-L1 expressers

Potentially Registrational Data

8

slide-9
SLIDE 9

NOT FOR PRODUCT PROMOTIONAL USE

2016: Diversifying in Immuno-Oncology

Patients who do not respond to Opdivo +/- Yervoy Patients who progress after treatment with Opdivo +/- Yervoy Additional tumors, including where signals are not sufficient Improve outcomes through combinations

Next wave of innovation: addressing unmet need

9

slide-10
SLIDE 10

NOT FOR PRODUCT PROMOTIONAL USE

8 Additional I-O Assets in Clinical Development

2016: Diversifying in Immuno-Oncology

NK cell T cell BMS assets beginning clinical studies in 2016

Tumor Microenvironment T Cell Activation NK Cell Activation

Next wave of innovation: areas of focus

Priming & Activation Antigen Presentation Antigen Release T Cell Trafficking and Infiltration

anti-CSF1R IDO anti-CD73 anti-LAG3 Urelumab (anti-CD137) anti-GITR anti-OX40 Lirilumab (anti-KIR)

10

slide-11
SLIDE 11

NOT FOR PRODUCT PROMOTIONAL USE

0% 10% 20% 30% 40% 50% 60% 70% 80% 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15

AF/VTE-Tx Share

0% 10% 20% 30% 40% 50% 60% 70% 80% 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15

AF/VTE-Tx Share

U.S. NBRx NOAC Market Share – Cardiologists (AFib + VTE-Tx) U.S. NBRx NOAC Market Share – All Physicians (AFib + VTE-Tx)

Note: Eliquis and Xarelto (all form strengths) are factored for AF and VTE-Tx indications. Pradaxa and Savaysa are unfactored and include volume across all approved indications. Source: IMS SDI VECTOR. NBRx (New to Brand Rx) = Naïve + Switch to Rx.

Pradaxa Total Eliquis AF/VTE-Tx Savaysa Total Xarelto AF/VTE-TX

Strong performance trends – establishing global leadership

11

slide-12
SLIDE 12

NOT FOR PRODUCT PROMOTIONAL USE

Genetically Defined Diseases

Monogenic diseases Sentinel populations

(eg, Duchenne Muscular Dystrophy, Progressive Supranuclear Palsy)

Cardiovascular

Heart Failure Thrombosis

Immunoscience

Novel mechanisms in RA and IBD Lupus

Fibrotic Diseases

Lung Liver Kidney

Pursuing Transformational Medicines Beyond Immuno-Oncology

12

slide-13
SLIDE 13

NOT FOR PRODUCT PROMOTIONAL USE

Capital Allocation: A Balanced Approach

Continue to be in a solid financial position:

  • Strong balance sheet
  • Business development remains a top priority
  • Dividend commitment
  • 7th consecutive annual increase

13

slide-14
SLIDE 14

NOT FOR PRODUCT PROMOTIONAL USE

Select Recent Partnerships

Immuno- science Fibrotic Diseases I-O Cardio- vascular Academic Partnerships

14

slide-15
SLIDE 15

NOT FOR PRODUCT PROMOTIONAL USE

BMS: Poised for Growth

Significant growth opportunity driven by I-O and Eliquis Strategic investments behind growth brands Advancing a diverse and innovative pipeline Balanced approach to capital allocation Focused business development

15

slide-16
SLIDE 16

NOT FOR PRODUCT PROMOTIONAL USE

JP Morgan Healthcare Conference

January 12, 2016

Giovanni Caforio

Chief Executive Officer

16